Eisai Invests in C₂N Diagnostics for Early Diagnosis of Alzheimer’s Disease

Eisai has made an investment up to $15 million in C₂N Diagnostics, a leader in advanced brain health diagnostics, to support C2N’s efforts to expand the availability, accessibility, affordability and utilization of blood-based tests for the diagnosis of Alzheimer’s disease (AD) in the US.

The presence of amyloid β (Aβ), a component of AD pathology, is currently confirmed using advanced diagnostic techniques such as positron emission tomography (PET) or by tests that require the collection of cerebrospinal fluid (CSF). By investing in C2N, Eisai seeks to support efforts to advance blood-based Aβ diagnostics that are accurate and affordable, providing new options for confirming the presence of Aβ.

The investment reflects the two companies’ shared desire to scale up and provide broad access to its Precivity™ tests, which are innovative blood tests intended for use in patients with cognitive impairment, to help healthcare providers determine Alzheimer’s disease pathology, and aid in medical management and treatment decisions.

With this financing, we’re building on our history of attracting the highest-quality investors committed to changing the trajectory of Alzheimer’s disease through early detection and treatment and, ultimately, prevention. We’re proud to have Eisai’s leadership in the field as we’re transforming the management and clinical care standard for patients with Alzheimer’s disease. The availability of blood biomarkers that are closely correlated with gold standard measures, such as positron emission tomography (PET) scans, will improve accessibility for patients to obtain safe and effective drug treatments as more become available,” said Dr. Joel Braunstein, CEO of C₂N Diagnostics.

“The field of highly accurate blood-based diagnostics is rapidly advancing and expanding,” said Keisuke Naito, Global Alzheimer’s Disease Officer, Senior Vice President, Eisai. “Given the expense and capacity limitations of PET and CSF tests, Eisai is working to support the dementia ecosystem’s growth. The availability of more affordable and minimally invasive diagnostic tools helps support broad access for the management of Alzheimer’s disease.”

en_GBEnglish (UK)